AstraZeneca (AZN) Share Forecast & Price Target

Compare

697 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AZN Analyst Ratings

Moderate Buy

11 Buy

4 Hold

0 Sell

Based on 15 analysts giving stock ratings to

AstraZeneca

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

13,125.00p

▲(29.39%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is 13,125.00p with a high forecast of 16,500.00p and a low forecast of 10,900.00p. The average price target represents a 29.39% change from the last price of 10,144.00p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10316":"10,316p","16501":"16,501p","11862.25":"11,862.3p","13408.5":"13,408.5p","14954.75":"14,954.8p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16500,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">17K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">13K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">11K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10316,11862.25,13408.5,14954.75,16501],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10574,11029.846153846154,11485.692307692309,11941.538461538461,12397.384615384615,12853.23076923077,13309.076923076924,13764.923076923078,14220.76923076923,14676.615384615385,15132.461538461539,15588.307692307691,16044.153846153848,{"y":16500,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10574,10770.23076923077,10966.461538461539,11162.692307692309,11358.923076923076,11555.153846153846,11751.384615384615,11947.615384615385,12143.846153846154,12340.076923076924,12536.307692307691,12732.538461538461,12928.76923076923,{"y":13125,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10574,10599.076923076924,10624.153846153846,10649.23076923077,10674.307692307691,10699.384615384615,10724.461538461539,10749.538461538461,10774.615384615385,10799.692307692309,10824.76923076923,10849.846153846154,10874.923076923076,{"y":10900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11941.55,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12053.23,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12256.99,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13085.44,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11630.62,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10863.79,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10402.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10317.74,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11181.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11968,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11366,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10608,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10574,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target16,500p

Average Price Target13,125p

Lowest Price Target10,900p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

11,999p

Buy

18.29%

Upside

Reiterated

06/24/25

AstraZeneca's strong financial performance and recent strategic corporate events drive a favorable outlook. Technical indicators suggest potential for upward momentum. Although the stock's valuation appears high, the robust earnings call and dividend support a solid investment case.

Justin SmithBernstein

Bernstein

16,500p

Buy

62.66%

Upside

Reiterated

06/26/25

AstraZeneca (AZN) Gets a Buy from Bernstein

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

11,000p

Hold

8.44%

Upside

Reiterated

06/24/25

Deutsche Bank Sticks to Its Hold Rating for AstraZeneca (AZN)

James GordonJ.P. Morgan

J.P. Morgan

14,000p

Buy

38.01%

Upside

Reiterated

06/24/25

J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)

Sachin JainBank of America Securities

Bank of America Securities

14,500p

Buy

42.94%

Upside

Reiterated

06/20/25

AstraZeneca's Promising Pipeline and Upcoming Catalysts Drive Buy Rating

Rajan SharmaGoldman Sachs

Goldman Sachs

―

Buy

―

Reiterated

06/10/25

AstraZeneca's Strong Strategic Positioning and Growth Potential Justifies Buy Rating

Matthew WestonUBS

UBS

14,200p

Buy

39.98%

Upside

Reiterated

06/03/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Emily FieldBarclays

Barclays

14,000p

Buy

38.01%

Upside

Reiterated

06/03/25

Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)

Seamus FernandezGuggenheim

Guggenheim

11,900p

Buy

17.31%

Upside

Reiterated

05/27/25

Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)

Luisa HectorBerenberg Bank

Berenberg Bank

14,000p

Buy

38.01%

Upside

Reiterated

05/16/25

Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)

Elmar KrausDZ BANK AG

DZ BANK AG

―

Hold

―

Reiterated

04/30/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Sarita KapilaMorgan Stanley

Morgan Stanley

14,500p→13,700p

Buy

35.06%

Upside

Reiterated

04/30/25

AstraZeneca price target lowered to 13,700 GBp at Morgan StanleyAstraZeneca price target lowered to 13,700 GBp at Morgan Stanley

David EvansKepler Capital

Kepler Capital

11,300p

Hold

11.40%

Upside

Reiterated

04/29/25

Kepler Capital Remains a Hold on AstraZeneca (AZN)

Benjamin Jackson CFAJefferies

Jefferies

10,900p

Hold

7.45%

Upside

Reiterated

04/29/25

AstraZeneca (AZN) Receives a Hold from Jefferies

Unknown AnalystShore Capital

Not Ranked

Shore Capital

―

Buy

―

Reiterated

04/29/25

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

11,999p

Buy

18.29%

Upside

Reiterated

06/24/25

Justin SmithBernstein

Bernstein

16,500p

Buy

62.66%

Upside

Reiterated

06/26/25

AstraZeneca (AZN) Gets a Buy from Bernstein

Emmanuel PapadakisDeutsche Bank

Deutsche Bank

11,000p

Hold

8.44%

Upside

Reiterated

06/24/25

Deutsche Bank Sticks to Its Hold Rating for AstraZeneca (AZN)

James GordonJ.P. Morgan

J.P. Morgan

14,000p

Buy

38.01%

Upside

Reiterated

06/24/25

J.P. Morgan Keeps Their Buy Rating on AstraZeneca (AZN)

Sachin JainBank of America Securities

Bank of America Securities

14,500p

Buy

42.94%

Upside

Reiterated

06/20/25

AstraZeneca's Promising Pipeline and Upcoming Catalysts Drive Buy Rating

Rajan SharmaGoldman Sachs

Goldman Sachs

―

Buy

―

Reiterated

06/10/25

AstraZeneca's Strong Strategic Positioning and Growth Potential Justifies Buy Rating

Matthew WestonUBS

UBS

14,200p

Buy

39.98%

Upside

Reiterated

06/03/25

UBS Reaffirms Their Buy Rating on AstraZeneca (AZN)

Emily FieldBarclays

Barclays

14,000p

Buy

38.01%

Upside

Reiterated

06/03/25

Barclays Sticks to Their Buy Rating for AstraZeneca (AZN)

Seamus FernandezGuggenheim

Guggenheim

11,900p

Buy

17.31%

Upside

Reiterated

05/27/25

Guggenheim Keeps Their Buy Rating on AstraZeneca (AZN)

Luisa HectorBerenberg Bank

Berenberg Bank

14,000p

Buy

38.01%

Upside

Reiterated

05/16/25

Berenberg Bank Reaffirms Their Buy Rating on AstraZeneca (AZN)

Elmar KrausDZ BANK AG

DZ BANK AG

―

Hold

―

Reiterated

04/30/25

AstraZeneca (AZN) Gets a Hold from DZ BANK AG

Sarita KapilaMorgan Stanley

Morgan Stanley

14,500p→13,700p

Buy

35.06%

Upside

Reiterated

04/30/25

AstraZeneca price target lowered to 13,700 GBp at Morgan StanleyAstraZeneca price target lowered to 13,700 GBp at Morgan Stanley

David EvansKepler Capital

Kepler Capital

11,300p

Hold

11.40%

Upside

Reiterated

04/29/25

Kepler Capital Remains a Hold on AstraZeneca (AZN)

Benjamin Jackson CFAJefferies

Jefferies

10,900p

Hold

7.45%

Upside

Reiterated

04/29/25

AstraZeneca (AZN) Receives a Hold from Jefferies

Unknown AnalystShore Capital

Not Ranked

Shore Capital

―

Buy

―

Reiterated

04/29/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

1 Month

xxx

Success Rate

23/43 ratings generated profit

Average Return

+0.31%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 53.49% of your transactions generating a profit, with an average return of +0.31% per trade.

3 Months

xxx

Success Rate

24/43 ratings generated profit

Average Return

+1.81%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 55.81% of your transactions generating a profit, with an average return of +1.81% per trade.

1 Year

Matthew WestonUBS

Success Rate

27/33 ratings generated profit

Average Return

+13.64%

reiterated a buy rating 25 days ago

Copying Matthew Weston's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +13.64% per trade.

2 Years

xxx

Success Rate

27/33 ratings generated profit

Average Return

+22.08%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +22.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AZN has received 38 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. AZN average Analyst price target in the past 3 months is 13,125.00.

Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is 1.63p with a range of 1.35p to 1.85p. The previous quarter’s EPS was 1.84p. AZN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is 10.39B with a range of 10.08B to 10.92B. The previous quarter’s sales results were 10.79B. AZN beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AZN has Outperformed its overall industry.

AZN Stock Forecast FAQ

What is GB:AZN’s average 12-month price target, according to analysts?

Based on analyst ratings, AstraZeneca plc’s 12-month average price target is 13,125.00.

What is GB:AZN’s upside potential, based on the analysts’ average price target?

AstraZeneca plc has 29.39% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is AstraZeneca plc a Buy, Sell or Hold?

AstraZeneca plc has a consensus rating of Moderate Buy, which is based on 11 buy ratings, 4 hold ratings and 0 sell ratings.

What is AstraZeneca plc’s share price target?

The average share price target for AstraZeneca plc is 13,125.00. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 16,500.00p ,and the lowest forecast is 10,900.00p. The average share price target represents 29.39% Increase from the current price of 10,144p.

What do analysts say about AstraZeneca plc?

AstraZeneca plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of AstraZeneca plc?

To buy shares of GB:AZN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

AstraZeneca (AZN) Share Forecast & Price Target

AZN Analyst Ratings

AZN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering AstraZeneca

AZN Analyst Recommendation Trends

AZN Financial Forecast

AZN Earnings Forecast

AZN Sales Forecast

AZN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts